High-dose aflibercept switch for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests whether switching to a higher dose of aflibercept (Eylea) is safe and effective for people with wet age-related macular degeneration who are already receiving standard-dose aflibercept. The goal is to see if the higher dose can better control the disease and possibly extend the time between injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have neovascular (wet) age-related macular degeneration in at least one eye.
- You have already had at least 3 initial (loading) and 2 follow-up (maintenance) injections of aflibercept (Eylea).
- You do not have other eye conditions that affect the macula, such as polyps, dystrophy, or scarring.
- You are not currently using a different anti-VEGF medication in your other eye, and you are not in another clinical trial.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
Hear when a new Wet Age-related Macular Degeneration (wAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.